following healthy diet plan, staying well hydrated, and exercising
This remains an actively moving area, however: on February 27, 2026, the HHS Secretary publicly announced an intent to move roughly 14 of the 19 Category 2-listed peptides, reportedly including ipamorelin and CJC-1295, back toward Category 1 status, and multiple industry and legal-news outlets reported further FDA action in the following months easing Category 2-related restrictions on this group of peptides
BPC-157 drives angiogenesis and anti-inflammatory signaling
Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3
At TRTMD, we take a personalized approach to every peptide therapy plantargeting inflammation, restoring balance, and supporting long-term vitality